2,434 Shares of BeOne Medicines Ltd. – Sponsored ADR $ONC Acquired by Hager Investment Management Services LLC

Hager Investment Management Services LLC bought a new stake in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) during the third quarter, HoldingsChannel reports. The institutional investor bought 2,434 shares of the company’s stock, valued at approximately $891,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Mather Group LLC. grew its position in shares of BeOne Medicines by 192.0% during the 3rd quarter. Mather Group LLC. now owns 73 shares of the company’s stock valued at $27,000 after acquiring an additional 48 shares during the period. GAMMA Investing LLC raised its holdings in shares of BeOne Medicines by 39.5% in the 3rd quarter. GAMMA Investing LLC now owns 120 shares of the company’s stock worth $44,000 after purchasing an additional 34 shares during the period. Parallel Advisors LLC raised its holdings in shares of BeOne Medicines by 24.0% in the 1st quarter. Parallel Advisors LLC now owns 351 shares of the company’s stock worth $104,000 after purchasing an additional 68 shares during the period. Provenance Wealth Advisors LLC bought a new stake in shares of BeOne Medicines in the 3rd quarter worth approximately $106,000. Finally, EverSource Wealth Advisors LLC lifted its stake in BeOne Medicines by 16.4% in the first quarter. EverSource Wealth Advisors LLC now owns 369 shares of the company’s stock valued at $110,000 after purchasing an additional 52 shares during the last quarter. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

More BeOne Medicines News

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: BeOne reported Q3 EPS of $3.64, above the $2.34 consensus, and revenue of $1.89 billion, topping estimates of $1.76 billion. The company also raised its 2026 revenue guidance, supporting a stronger outlook. Q3 earnings and guidance
• Positive Sentiment: The FDA granted priority review to a BRUKINSA combination for first-line mantle cell lymphoma. A faster review could bring a potential label expansion sooner, though approval is not guaranteed. FDA priority review
• Positive Sentiment: Several firms raised price targets while maintaining bullish ratings: RBC to $465, Citizens JMP to $463, Truist to $448, Barclays to $446, and Wells Fargo to $435. The revisions signal continued analyst confidence in BeOne’s prospects. RBC rating information Citizens JMP rating information Truist rating information Barclays rating information Wells Fargo rating information

Analyst Ratings Changes

Several equities analysts have weighed in on ONC shares. TD Cowen increased their price objective on BeOne Medicines from $424.00 to $454.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Royal Bank Of Canada boosted their target price on BeOne Medicines from $459.00 to $465.00 and gave the company an “outperform” rating in a research note on Friday. Jefferies Financial Group reaffirmed a “buy” rating and set a $470.00 price target on shares of BeOne Medicines in a research report on Thursday. Truist Financial reiterated a “buy” rating and set a $448.00 price target (up from $420.00) on shares of BeOne Medicines in a research note on Friday. Finally, Citigroup reiterated an “outperform” rating on shares of BeOne Medicines in a research note on Thursday, August 6th. Sixteen research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $434.79.

BeOne Medicines Stock Performance

NASDAQ ONC opened at $406.96 on Monday. The company’s 50 day moving average is $363.49 and its 200-day moving average is $326.34. BeOne Medicines Ltd. – Sponsored ADR has a 12-month low of $253.95 and a 12-month high of $410.71. The company has a quick ratio of 3.19, a current ratio of 3.55 and a debt-to-equity ratio of 0.14. The firm has a market cap of $44.68 billion, a P/E ratio of 51.71 and a beta of 0.63.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings results on Thursday, November 5th. The company reported $3.64 EPS for the quarter, beating analysts’ consensus estimates of $2.34 by $1.30. The company had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.76 billion. BeOne Medicines had a net margin of 13.86% and a return on equity of 19.04%. Sell-side analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 8.99 earnings per share for the current year.

Insider Buying and Selling at BeOne Medicines

In other news, insider Titus B. Ball sold 132 shares of the firm’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $355.86, for a total value of $46,973.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John Oyler sold 54,892 shares of BeOne Medicines stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $358.15, for a total value of $19,659,569.80. Following the completion of the transaction, the chief executive officer owned 240,743 shares of the company’s stock, valued at approximately $86,222,105.45. This trade represents a 18.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 261,362 shares of company stock worth $93,689,167. Company insiders own 6.19% of the company’s stock.

About BeOne Medicines

BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia.

Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer.